Next-morning impairment leads to lower doses for zolpidem sleep aids
This article was originally published in Scrip
Executive Summary
US regulators on 10 January told makers of sedative-hypnotic sleep aids containing zolpidem, such as Sanofi's Ambien, to lower the recommended dose in labeling for women from 10mg to 5mg for immediate-release products and from 12.5mg to 6.25mg for extended-release medicines because of the risk of next-morning impairment.